Literature DB >> 11857749

Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: a founder mutation of BRCA1 identified in the Chinese population.

Ui-Soon Khoo1, Kelvin Y K Chan, Annie N Y Cheung, W C Xue, D H Shen, K Y Fung, Hextan Y S Ngan, K W Choy, C P Pang, C S P Poon, A Y A Poon, Hilmi Ozcelik.   

Abstract

Previous mutational analysis for BRCA gene mutations in sporadic ovarian cancer occurring in Chinese patients in Hong Kong identified six germline BRCA1 mutations and one germline BRCA2 mutation, six of which were novel (Khoo et al., 2000). Knowledge of BRCA gene mutations in the Chinese population is relatively scant. In this study, we focussed on whether any of these mutations could be recurrent in our Chinese population, making use of archival paraffin embedded tissue. A consecutive series of 214 ovarian cancer cases, half of Southern Chinese origin from Hong Kong whilst the other half of Northern Chinese origin from Beijing were used for the study. We identified one further novel mutation, 1081delG, in BRCA1. This was found to occur in two unrelated individuals with shared haplotype as revealed by allelotype analysis, thus demonstrating founder effect. Two other recurrent mutations were also identified, the 2371-2372delTG mutation in BRCA1 and the 3337C>T mutation in BRCA2 recurring in two and three unrelated individuals respectively, giving an overall prevalence 4.7% of recurrent BRCA mutations in ovarian cancer in the Southern Chinese population. Most importantly, all our recurrent mutation carriers were identified from Southern Chinese patients from Hong Kong whilst such mutations were absent in samples from the Northern Chinese. Our findings indicate possible heterogeneity in the BRCA genotype between Northern and Southern Chinese. The identification of a founder mutation and two recurrent mutations moreover, has important implications towards screening strategies for breast and ovarian cancer among Chinese of southern ancestral origin who are now dispersed throughout the world. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 11857749     DOI: 10.1002/humu.9015

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  22 in total

Review 1.  Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms.

Authors:  H Wu; X Wu; Z Liang
Journal:  Gene Ther       Date:  2017-08-03       Impact factor: 5.250

Review 2.  Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries.

Authors:  Ava Kwong; Vivian Y Shin; John C W Ho; Eunyoung Kang; Seigo Nakamura; Soo-Hwang Teo; Ann S G Lee; Jen-Hwei Sng; Ophira M Ginsburg; Allison W Kurian; Jeffrey N Weitzel; Man-Ting Siu; Fian B F Law; Tsun-Leung Chan; Steven A Narod; James M Ford; Edmond S K Ma; Sung-Won Kim
Journal:  J Med Genet       Date:  2015-07-17       Impact factor: 6.318

3.  PGD for hereditary breast and ovarian cancer: the route to universal tests for BRCA1 and BRCA2 mutation carriers.

Authors:  Marion Drüsedau; Jos C Dreesen; Inge Derks-Smeets; Edith Coonen; Ron van Golde; Jannie van Echten-Arends; Peter M M Kastrop; Marinus J Blok; Encarna Gómez-García; Joep P Geraedts; Hubert J Smeets; Christine E de Die-Smulders; Aimée D Paulussen
Journal:  Eur J Hum Genet       Date:  2013-03-27       Impact factor: 4.246

4.  A novel frequent BRCA1 allele in Chinese patients with breast cancer.

Authors:  Dongxian Zhou; Wen Xiong; Hongxan Xu; Chaopeng Shao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

5.  EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.

Authors:  Tao Li; Jing Cai; Hui Ding; Linjuan Xu; Qiang Yang; Zehua Wang
Journal:  Cancer Biol Ther       Date:  2013-12-12       Impact factor: 4.742

6.  Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry.

Authors:  Bifeng Zhang; James D Fackenthal; Qun Niu; Dezheng Huo; Walmy E Sveen; Tiffani DeMarco; Clement A Adebamowo; Temidayo Ogundiran; Olufunmilayo I Olopade
Journal:  Fam Cancer       Date:  2008-08-05       Impact factor: 2.375

7.  Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan.

Authors:  Alexander Liede; Imtiaz A Malik; Zeba Aziz; Patricia de los Rios Pd; Elaine Kwan; Steven A Narod
Journal:  Am J Hum Genet       Date:  2002-08-13       Impact factor: 11.025

Review 8.  Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review.

Authors:  Carlos Andrés Ossa; Diana Torres
Journal:  Oncologist       Date:  2016-06-10

9.  Novel germline mutations in BRCA2 gene among 96 hereditary breast and breast-ovarian cancer families from Kerala, South India.

Authors:  Vani Syamala; Leelakumari Sreeja; Volga S Syamala; B Vinodkumar; Praveenkumar B Raveendran; Hariharan Sreedharan; Ratheesan Kuttappan; Lekshmi Balakrishnan; Ravindran Ankathil
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-15       Impact factor: 4.553

10.  Prevalence of BRCA1 and BRCA2 mutations in Korean breast cancer patients.

Authors:  Sei Hyun Ahn; Ui Kang Hwang; Beom Seok Kwak; Ho Sung Yoon; Bo Kyung Ku; Hee Jun Kang; Ji Su Kim; Byung Kyun Ko; Chang Dae Ko; Kyung Sik Yoon; Dae-Yeon Cho; Jun Suk Kim; Byung Ho Son
Journal:  J Korean Med Sci       Date:  2004-04       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.